L
Lemieux Rene M
Researcher at Agios Pharmaceuticals
Publications - 17
Citations - 396
Lemieux Rene M is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Glutaminase & Cancer. The author has an hindex of 6, co-authored 17 publications receiving 298 citations. Previous affiliations of Lemieux Rene M include Schrödinger.
Papers
More filters
Journal ArticleDOI
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller,Lemieux Rene M,Erin Artin,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Giovanni Cianchetta,Zhenwei Cai,Ding Zhou,Cui Dawei,Ping Chen,Kimberly Straley,Erica Tobin,Fang Wang,Muriel D. David,Virginie Penard-Lacronique,Cyril Quivoron,Véronique Saada,Stéphane de Botton,Stefan Gross,Lenny Dang,Hua Yang,Luke Utley,Yue Chen,Hyeryun Kim,Shengfang Jin,Zhiwei Gu,Gui Yao,Zhiyong Luo,Xiaobing Lv,Cheng Fang,Liping Yan,Andrew J. Olaharski,Lee Silverman,Scott A. Biller,Shinsan M. Su,Katharine E. Yen +36 more
TL;DR: AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo is reported.
Journal ArticleDOI
AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
Erica Hansen,Cyril Quivoron,Cyril Quivoron,Cyril Quivoron,Kim Straley,Lemieux Rene M,Janeta Popovici-Muller,Hossein Sadrzadeh,Amir T. Fathi,Camelia Gliser,Muriel D. David,Muriel D. David,Muriel D. David,Véronique Saada,Véronique Saada,Véronique Saada,Jean-Baptiste Micol,Jean-Baptiste Micol,Olivier Bernard,Olivier Bernard,Olivier Bernard,Marion Dorsch,Hua Yang,Michael Su,Sam Agresta,Stéphane de Botton,Stéphane de Botton,Stéphane de Botton,Virginie Penard-Lacronique,Katharine E. Yen +29 more
TL;DR: It is demonstrated that AG-120 is effective at lowering 2-HG levels and restoring cellular differentiation, and support further clinical development of this compound, suggesting that cancer-associated IDH mutations may induce a block in cellular differentiation to promote tumorigenesis.
Patent
Compounds and their methods of use
Lemieux Rene M,Janeta Popovici-Muller,Francesco G. Salituro,Jeffrey O. Saunders,Jeremy Travins,Chen Yongsheng +5 more
TL;DR: In this article, compounds and compositions comprising compounds that inhibit glutaminase are described and methods of using the compounds in the treatment of cancer are described. But none of them are described in detail.
Patent
Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof
Lemieux Rene M,Chen Yongsheng +1 more
TL;DR: In this paper, compounds of formula (I) are defined as in the description, wherein X, Y, Z, W, m, n, o, p, R 1, R 2 and R 6 are defined.
Patent
Glutamase inhibitors and method of use
Lemieux Rene M,Janeta Popovici-Muller,Francesco G. Salituro,Jeffrey O. Saunders,Jeremy Travins,Shunqi Yan +5 more
TL;DR: In this article, compounds and compositions comprising compounds that inhibit glutaminase are described and methods of using the compounds in the treatment of cancer are described. But none of them are described in detail.